ANAC
Anacor Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, May 20, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    | Fri, May 20, 7:32 AM | 10 Comments
  • Mon, May 16, 12:51 PM
    | Mon, May 16, 12:51 PM
  • Mon, May 16, 9:19 AM
    | Mon, May 16, 9:19 AM | 8 Comments
  • Mon, May 16, 7:14 AM
    | Mon, May 16, 7:14 AM | 18 Comments
  • Tue, May 10, 9:59 AM
    • Anacor Pharmaceuticals (ANAC +0.9%) Q1 results: Revenues: $17.5M (+14.4%); R&D Expense: $19.4M (+6.6%); SG&A: $12.2M (+50.6%); Operating Loss: ($14.9M) (-26.3%); Net Loss: ($16.1M) (-23.8%); Loss Per Share: ($0.36) (-20.0%); Quick Assets: $137.9M (-4.5%).
    • No guidance given.
    | Tue, May 10, 9:59 AM
  • Tue, May 10, 7:01 AM
    • Anacor Pharmaceuticals (NASDAQ:ANAC): Q1 EPS of -$0.36 misses by $0.01.
    • Revenue of $17.54M (+14.9% Y/Y) misses by $1.99M.
    | Tue, May 10, 7:01 AM
  • Mon, May 9, 5:30 PM
  • Tue, Apr. 19, 12:49 PM
    | Tue, Apr. 19, 12:49 PM | 5 Comments
  • Fri, Apr. 1, 7:01 AM
    • Anacor Pharmaceuticals (NASDAQ:ANAC) prices its $250M aggregate principal amount of 2.00% Convertible Senior Notes due 2023. Initial purchasers have a 30-day option to buy an up to an additional $37.5M of the Notes. Closing date is April 6. Net proceeds should be ~$241.6M.
    • The initial conversion rate will be 14.1201 shares of common stock per $1,000 principal amount of the Notes (~$70.82 per share).
    • In order to reduce potential dilution and/or to offset any cash payments, the company has entered into capped call transactions with certain financial institutions. The cap price will initially be $80.18 per share. The cost of the transactions should be ~$14M.
    • Yesterday's close was $53.51.
    | Fri, Apr. 1, 7:01 AM
  • Wed, Mar. 30, 4:05 PM
    • Anacor Pharmaceuticals (NASDAQ:ANAC) initiates a private offering of $250M aggregate principal amount of Convertible Senior Notes due 2023. Initial purchasers will have a 30-day option to buy up to an additional $37.5M of the Notes.
    • Price, interest rate and terms have yet to be announced.
    | Wed, Mar. 30, 4:05 PM
  • Tue, Mar. 22, 8:26 PM
    • The FDA accepts for review Anacor Pharmaceuticals' (NASDAQ:ANAC) New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2% for the treatment of mild-to-moderate atopic dermatitis in adults and children. The agency's action date (PDUFA date) is January 7, 2017.
    • Crisaborole topical ointment, 2% is a non-steroidal anti-inflammatory treatment that inhibits a family of enzymes called phosphodiesterase 4 (PDE-4). Inhibiting PDE-4 reduces the production of pro-inflammatory proteins called cytokines (e.g., interleukins) believed to play key roles in the signs and symptoms of atopic dermatitis.
    | Tue, Mar. 22, 8:26 PM | 4 Comments
  • Fri, Mar. 18, 11:52 AM
    • Insmed (INSM -0.7%) initiated with Buy rating and $23 (105% upside) price target by Stifel Nicolaus.
    • Regeneron Pharmaceuticals (REGN +0.8%) initiated with Buy rating and $574 (57% upside) price target by Gabelli & Co.
    • RegenRx Biopharmaceuticals (OTCQB:RGRX -7.9%) initiated with Buy rating and $2 (245% upside) price target by Rodman & Renshaw.
    • Anacor Pharmaceuticals (ANAC -1.8%) initiated with Buy rating and $103 (84% upside) price target by Mizuho Securities.
    • Acura Pharmaceuticals (ACUR) initiated with Buy rating and $6 (183% upside) price target by Roth Capital.
    • NeoGenomics (NEO -0.2%) initiated with Buy and $8 (26% upside) price target by Benchmark.
    • Depomed (DEPO -0.5%) initiated with Outperform rating and $21 (62% upside) price target by Leerink Swann.
    • Galectin Therapeutics (GALT +1.6%) initiated with Buy and $6 (380% upside) price target by Roth Capital.
    | Fri, Mar. 18, 11:52 AM
  • Mon, Feb. 29, 5:45 PM
    | Mon, Feb. 29, 5:45 PM | 4 Comments
  • Mon, Feb. 29, 4:07 PM
    • Anacor Pharmaceuticals (NASDAQ:ANAC): Q4 EPS of -$0.43 misses by $0.13.
    • Revenue of $21.2M (+119.9% Y/Y) misses by $6.73M.
    | Mon, Feb. 29, 4:07 PM
  • Sun, Feb. 28, 5:35 PM
  • Nov. 3, 2015, 7:17 AM
    • Anacor Pharmaceuticals (NASDAQ:ANAC): Q3 EPS of -$0.37 misses by $0.09.
    • Revenue of $24.55M (+519.9% Y/Y) misses by $0.72M.
    | Nov. 3, 2015, 7:17 AM | 1 Comment